GlassScriptPhysician profile
Lowell Evan Michael
NPI 1942516992
$1,418.05
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $43.74.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $501.10 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $297.81 | 2019 | |
| Genzyme Corporation | $168.22 | 2019 | |
| Abbvie INC. | $122.71 | 2019-2020 | |
| Lilly USA, LLC | $93.79 | 2019 | |
| Galderma Laboratories, L.P. | $71.71 | 2019 | |
| Sun Pharmaceutical Industries INC. | $51.63 | 2019 | |
| Celgene Corporation | $22.45 | 2019 | |
| Dermira, INC. | $22.21 | 2020 | |
| Prugen, INC. Pharmaceuticals | $21.83 | 2019 | |
| Pfizer INC. | $17.04 | 2019 | |
| Amgen INC. | $16.52 | 2019 | |
| Promius Pharma LLC | $11.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.